TRVI - Trevi rises 10% on completing enrollment in phase 2b/3 study of Haduvio for pruritus

Trevi Therapeutics (TRVI +9.8%) completed enrollment in its phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for pruritus associated with prurigo nodularis (PN). PN is a chronic inflammatory skin disease where an extremely itchy rash appears on parts of the body. The company expects to report top-line data in the Q2 2022. "By targeting the pruritus associated with prurigo nodularis, Haduvio is designed to break the itch-scratch cycle which has a significant impact on patients' quality of life," said President and CEO Jennifer Good. The U.S. Food and Drug Administration has granted fast track designation to nalbuphine ER for reducing moderate to severe pruritus in patients with PN.

For further details see:

Trevi rises 10% on completing enrollment in phase 2b/3 study of Haduvio for pruritus